Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCAYXF)

Drug Name
alpha-methyl-5-HT Drug Info
Synonyms alpha-Me-5-HT; alpha-methylserotonin
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2107
ChEBI ID
CHEBI:48295
CAS Number
CAS 304-52-9
TTD Drug ID
DMCAYXF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [10]
Eletriptan DMW649X Migraine 8A80 Approved [11]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [11]
Frovatriptan DM7RE8P Migraine 8A80 Approved [11]
Sumatriptan DMVYXR8 Migraine 8A80 Approved [12]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [13]
Almogran DM7I64Z Migraine 8A80 Approved [14]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [15]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [16]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [18]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [19]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [20]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [21]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [20]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [22]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [23]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [19]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [24]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [25]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [26]
Triflupromazine DMKFQJP Psychotic disorder 6A20-6A25 Approved [27]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [28]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [29]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [30]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [31]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [32]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [32]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [32]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [26]
Zotepine DMF3VXA Anxiety disorder 6B00-6B0Z Approved [33]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [34]
Flibanserin DM70DTN Mood disorder 6A60-6E23 Approved [35]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [36]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [37]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [38]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [39]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [40]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 4 receptor (HTR4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisapride DMY7PED Gastroesophageal reflux disease DA22.Z Approved [42]
Tegaserod DM3XYD1 Irritable bowel syndrome DD91.0 Approved [43]
R0-93877 DMM4U9G Constipation DD91.1 Approved [12]
HTF 919 DM78G6F Constipation DD91.1 Approved [44]
Mosapride DM2VOQ3 N. A. N. A. Phase 4 [45]
Renzapride DM7HQNX Irritable bowel syndrome DD91.0 Phase 3 [46]
Lintopride DMSHGWN Nausea MD90 Phase 2 [47]
TD-8954 DM3C9NV Gastrointestinal disease DE2Z Phase 2 [48]
SB-207266A DM27KFY Irritable bowel syndrome DD91.0 Phase 2 [12]
YKP-GI DM740LV Constipation DD91.1 Phase 2 [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1F receptor (HTR1F)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [50]
Lasmiditan DMXLVDT Migraine 8A80 Approved [51]
LY-334370 DM43O9N Migraine 8A80 Phase 2 [52]
5-CT DM260KD Discovery agent N.A. Investigative [50]
TFMPP DMAC8TP Discovery agent N.A. Investigative [4]
1-naphthylpiperazine DM6BIWK Discovery agent N.A. Investigative [50]
BRL-15572 DMM61Y2 Discovery agent N.A. Investigative [53]
2-methyl-5-HT DM1S5CB N. A. N. A. Investigative [4]
WAY-466 DMMOH51 Discovery agent N.A. Investigative [54]
[125I]LSD DMP69QG Discovery agent N.A. Investigative [55]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2C receptor (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [26]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [56]
Tramadol DMRQD04 Pain MG30-MG3Z Approved [57]
Mirtazapine DML53ZJ Depression 6A70-6A7Z Approved [58]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [59]
Methysergide DM1EF73 Migraine 8A80 Approved [60]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [61]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [62]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [63]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1E receptor (HTR1E)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [3]
5-CT DM260KD Discovery agent N.A. Investigative [3]
TFMPP DMAC8TP Discovery agent N.A. Investigative [3]
1-naphthylpiperazine DM6BIWK Discovery agent N.A. Investigative [3]
BRL-15572 DMM61Y2 Discovery agent N.A. Investigative [53]
2-methyl-5-HT DM1S5CB N. A. N. A. Investigative [4]
m-chlorophenylpiperazine DMM1J2D Discovery agent N.A. Investigative [3]
EDMT DMS3AXK Discovery agent N.A. Investigative [64]
9-OH-risperidone DMGORXQ Discovery agent N.A. Investigative [65]
[3H]5-HT DMYJXV7 Discovery agent N.A. Investigative [66]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [2]
5-HT 1E receptor (HTR1E) TTCPG9S 5HT1E_HUMAN Agonist [3]
5-HT 1F receptor (HTR1F) TT0MI3F 5HT1F_HUMAN Agonist [4]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Agonist [5]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Agonist [6]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Agonist [7]
5-HT 4 receptor (HTR4) TT07C3Y 5HT4R_HUMAN Agonist [8]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Agonist [9]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 152).
2 Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80.
3 Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
4 Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
5 Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol. 2000 Nov;58(5):877-86.
6 The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60.
7 High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999 May;72(5):2127-34.
8 [3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. Neuropharmacology. 1997 Apr-May;36(4-5):671-9.
9 Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem. 1998 Nov;71(5):2169-77.
10 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
13 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
14 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
15 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Company report (NeurAxon)
18 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
19 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
20 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
21 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
22 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
23 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
24 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
25 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
26 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
27 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
28 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
29 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
30 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
31 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
32 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
33 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
34 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
35 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
36 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
37 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
38 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
39 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
40 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
41 Clinical pipeline report, company report or official report of Lundbeck.
42 Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
43 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
44 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
45 The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
46 Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
47 The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
48 The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
49 A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.
50 Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76.
51 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
52 Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001 Oct 13;358(9289):1230-4.
53 SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
54 Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
55 Isolation of a mouse "5HT1E-like" serotonin receptor expressed predominantly in hippocampus. J Biol Chem. 1992 Oct 5;267(28):19761-4.
56 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
57 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
58 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
59 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
60 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
61 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
62 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
63 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
64 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
65 Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
66 Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5517-21.